JAZZ News and Press, Jazz Pharmaceuticals plc From 01/28/24

2024-01-28 02:56:55 ET Summary Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential...

2024-01-23 07:11:07 ET More on Apple Apple Faces Major Potential Risks Apple Stock: The Market Ignores The Obvious Is Everyone Sleeping On Apple's Real Potential In 2024? (Rating Upgrade) Apple said to pay $13.7M fine to Russia over alleged in-app payment abu...

2024-01-19 01:30:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

2024-01-18 11:00:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

2024-01-11 11:31:29 ET Summary Avadel Pharma's launch of its product LUMRYZ is expected to drive the company's stock performance. LUMRYZ appears to have momentum and is differentiated from current narcolepsy treatments. The potential revenue for Avadel from LUMRYZ could ultima...

2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...

2023-12-21 16:25:06 ET Jazz Pharmaceuticals ( NASDAQ: JAZZ ) on Thursday said a mid-stage trial of its investigational therapy for the treatment of post-traumatic stress disorder (PTSD) failed to meet the main goal of the study, sending its shares falling as much as ~6% aft...

Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder PR Newswire DUBLIN , Dec. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from ...

2023-12-21 07:24:53 ET Summary Jazz Pharmaceuticals' market valuation is fairly conservative overlooking its promising potential. Zanidatamab's Phase 2a success boosts Jazz's oncology market potential. Despite challenges, Jazz's strategic positioning and conservative market va...

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42 nd...